Provided by Tiger Trade Technology Pte. Ltd.

ZAI LAB

19.440
-0.360-1.82%
Volume:4.22M
Turnover:82.37M
Market Cap:22.12B
PE:-15.47
High:19.940
Open:19.800
Low:19.300
Close:19.800
52wk High:27.280
52wk Low:12.310
Shares:1.14B
HK Float Shares:1.14B
Volume Ratio:0.59
T/O Rate:0.37%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.257
ROE:-26.91%
ROA:-14.75%
PB:4.65
PE(LYR):-15.47
PS:6.28

Loading ...

HK Movers | Biotech Stocks Jump. Wuxi Apptec Soars 14% as 1Q Net Profit Rises 26.7%; Junshi Bio up 8%; Asymchem up Nearly 7%; Pharmaron up 4%

Tiger Newspress
·
Apr 28

Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading

MT Newswires Live
·
Apr 23

Zai Lab to Review and Publish Q1 2026 Results on 7 May; Earnings Call Scheduled Same Day

Bulletin Express
·
Apr 23

HK Biotech Stocks Fell. Akeso Down 12%; Remegen, Zai Lab, KeyMed And Junshi Down 7%; Lepu And Innocare Down 6%

Tiger Newspress
·
Apr 23

Zai Lab to report first-quarter results, host conference call

Reuters
·
Apr 22

Zai Lab publishes AACR presentation highlighting DLL3 ADC ZL-1310 in SCLC brain metastases

Reuters
·
Apr 20

Zai Lab Shares Climb Over 5% on Positive Preclinical Data for ZL-1503

Stock News
·
Apr 20

Stock Track | Zai Lab Soars 5.25% Intraday on Clinical Collaboration with Boehringer Ingelheim

Stock Track
·
Apr 20

Zai Lab starts Phase 1/1b trial of ZL-1503 bispecific antibody in atopic dermatitis

Reuters
·
Apr 18

Zai Lab says zoci posts 53.7% intracranial response rate in SCLC brain metastases trial

Reuters
·
Apr 18

Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer With Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas

THOMSON REUTERS
·
Apr 18

Zai Lab announces annual shareholder meeting

Reuters
·
Apr 17

Stock Track | Zai Lab Soars 5.05% Intraday on Clinical Collaboration with Boehringer Ingelheim for Novel Cancer Therapy

Stock Track
·
Apr 16

Zai Lab Shares Climb Over 4% on Partnership with Boehringer Ingelheim for Novel Dual DLL3-Targeting Combination Therapy

Stock News
·
Apr 16

Asian Equities Traded in the US as American Depositary Receipts Track Higher in Wednesday Trading

MT Newswires Live
·
Apr 15

Zai Lab, Boehringer Ingelheim team up on DLL3 combo trial in lung cancer

Reuters
·
Apr 15

Boehringer Ingelheim and Zai Lab Announce Collaboration on Dll3‑Targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

THOMSON REUTERS
·
Apr 15

Zai Lab Ltd: Under Agreement, Co to Supply Dll3‑Targeting ADC for Study, Boehringer to Sponsor & Oversee Day‑to‑Day Clinical Operations

THOMSON REUTERS
·
Apr 15

Zai Lab Shares Climb Over 3% Following Global Clinical Partnership with Amgen for Zoci Candidate

Stock News
·
Apr 14

Zai Lab Boosts Issued Share Base by 6.00 Million in March; Public Float Remains Above 25%

Bulletin Express
·
Apr 08